Superior Performance of Newly Developed Alinity Anti‐HCV Next Assay in the Diagnosis of HCV Infection
- 18 March 2025
- journal article
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (3) , e70307
Abstract
World Health Organization recommends anti‐HCV antibody testing for primary screening to be followed by HCV‐RNA. However, current serological assays are prone to false‐positive results. We ascertained the ability of the newly developed Abbott Alinity‐i anti‐HCV Next assay (Research‐Use‐Only) to resolve false‐positives and profiled its performance edges. Samples ( n = 2186) received from January to June 2024 were subjected to anti‐HCV testing using Architect and anti‐HCV Next (Abbott), and LIAISON XL MUREX HCV antibody assays. Samples were categorized based on the signal to cutoff (S/CO) of on‐market anti‐HCV assays (Architect and Liaison) as negative Architect ( n = 1537), equivocal Architect ≥1/Liaison‐ ( n = 226), low‐positive Architect+ ≥1 to ( n = 228) and high‐positive Architect ≥8/Liaison+ ( n = 195). Hepatitis C virus core antigen (HCVcAg) and HCV‐RNA were quantified using Architect HCVcAg and Abbott real‐time PCR, respectively. Performance on seroconversion and proficiency testing panels were assessed. Significant proportion of equivocal (99%) & low‐positive (76.3%) samples were negative in Next ( p < 0.0001). The signal intensities of Next were significantly lower for true‐negative and higher for positives than the other two assays ( p < 0.0001). Next exhibited superior (10–12 days) seroconversion sensitivity (2/4 panels) and comparable performance between genotypes ( p > 0.05). Our findings suggest that the newly developed anti‐HCV Next assay is configured better to resolve challenging false‐positives and to achieve exquisite sensitivity, thereby reducing the burden/cost of retesting and expensive reflex testing for the effective cascade of care.Keywords
Funding Information
- Abbott Laboratories
This publication has 11 references indexed in Scilit:
- Updated Operational Guidance for Implementing CDC’s Recommendations on Testing for Hepatitis C Virus InfectionMMWR. Morbidity and Mortality Weekly Report, 2023
- Evaluating the utility of a two‐assay serological algorithm for hepatitis C screening in a low prevalence populationJournal of Clinical Laboratory Analysis, 2023
- Longitudinal assessment of HCV core antigen kinetics to monitor therapeutic response in the age of DAAsPLOS ONE, 2023
- Clinical utility of hepatitis C virus core antigen (HCVcAg) assay to identify active HCV infection in hemodialysis and renal transplant patientsPLOS ONE, 2021
- The role of a two-assay serological testing strategy for anti-HCV screening in low-prevalence populationsScientific Reports, 2021
- HCV core antigen plays an important role in the fight against HCV as an alternative to HCV‐RNA detectionJournal of Clinical Laboratory Analysis, 2021
- From hepatitis C virus immunoproteomics to rheumatology via cross-reactivity in one tableCurrent Opinion in Rheumatology, 2019
- Diagnostic reliability of Architect anti‐HCV assay: Experience of a tertiary care hospital in IndiaJournal of Clinical Laboratory Analysis, 2017
- Prevalence of false-positive hepatitis C antibody results, National Health and Nutrition Examination Study (NHANES) 2007–2012Journal of Clinical Virology, 2017
- Comparison of Three Different Hepatitis C Virus Genotyping Methods: 5′NCR PCR‐RFLP, Core Type‐Specific PCR, and NS5b Sequencing in a Tertiary Care Hospital in South IndiaJournal of Clinical Laboratory Analysis, 2016